Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cisco Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Cisco Systems Inc trades at $121.13 (market cap $478.14B). The key difference: Cisco Systems Inc is far larger — about 12× Alnylam Pharmaceuticals, Inc.'s market cap, and Cisco Systems Inc pays a 1.38% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CSCO | |
|---|---|---|
Market Cap | $39.89B | $478.14B |
Sector | Health | Technology |
52-Week High | $491.22 | $130.00 |
52-Week Low | $278.09 | $66.20 |
Enterprise Value | $38.15B | $492.80B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Cisco Systems (CSCO) trades at $121.31, up 2.54% on the day, approaching its 52-week high with strong technical momentum. The stock shows bullish moving average signals and has consistently beaten earnings expectations in recent quarters. Recent AI cybersecurity partnerships and product launches, including Cisco Cloud Control, are driving positive sentiment. Valuation ratios remain elevated with a P/E of 40.44 and P/S of 7.96, reflecting growth expectations in networking and security segments.
Outlook remains positive with a consensus price target of $130.38, though high valuation multiples and competitive pressures pose risks. Revenue growth is projected to reach $60.7B in 2026 with improved margins. Institutional ownership is strong, but investors should monitor execution on AI initiatives and debt levels, which have increased recently.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
